In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

What if machines could not only learn but also teach themselves to become better with each iteration? This isn’t the plot of a sci-fi movie—it’s the reality unfolding in artificial intelligence ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

When you’re done with this week’s material, please take Quiz 01. To prepare, you should read the syllabus and all specified readings in the book, watch all video lectures, and review all source code ...

When you’re done with this week’s material, please take Quiz 02. To prepare, you should complete read/view all content for this week. The quiz will focus primarily on this week but may also have some ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...

ABSTRACT: We prove that non-recursive base conversion can always be implemented by using a deterministic Markov process. Our paper discusses the pros and cons of recursive and non-recursive methods, ...